Lebrikizumab Asthma Market Forecast and Analysis to 2023

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (Lebrikizumab (Asthma) – Forecast and Market Analysis to 2023) / report name in subject line and your contact details.

Researcher has released its new PharmaPoint Drug Evaluation report, "Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Roche's lebrikizumab is under development for the treatment of patients with moderate to severe asthma who respond poorly to medium or high doses of ICSs. Lebrikizumab is a first-in-class immunoglobulin G4 (IgG4) humanized mAb that specifically binds to and inhibits the activity of IL-13. IL-13 is a pleiotropic cytokine of the Th2 cell response that contributes to asthma pathogenesis via increased chemokine secretion and mucus hyperexcretion, increased cholinergic-induced contractions, and smooth muscle proliferation (Khurana Hershey, 2003). Clinical studies have correlated the presence of elevated periostin levels with the increased efficacy of lebrikizumab.

Complete report is available @ http://www.reportsnreports.com/reports/298114-lebrikizumab-asthma-forecast-and-market-analysis-to-2023.html .

Scope

• Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Lebrikizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Lebrikizumab for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to Buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Asthma
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Lebrikizumab performance
• Obtain sales forecast for Lebrikizumab from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=298114 .

Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Unmet Need and Opportunity
6.1 Overview
6.2 Personalized Therapies to Control Severe Asthma
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Better Patient Compliance
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Lower Cost of Asthma Medications
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Proper Diagnosis of Asthma in Children
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Lebrikizumab
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Asthma Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions

Request Sample of this report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=298114 .

(For Single User License: US$ 3495 And Corporate User License: US$ 10485)

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Lebrikizumab (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.